ClinConnect ClinConnect Logo
Search / Trial NCT06263426

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Launched by JOHNS HOPKINS UNIVERSITY · Feb 9, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, called the Expanding HOPE Kidney study, is exploring how kidney transplants from donors with HIV affect patients who also have HIV. The goal is to understand whether receiving a kidney from an HIV-positive donor leads to different outcomes, such as rejection of the kidney, compared to receiving a kidney from a donor without HIV. Researchers are particularly interested in the long-term effects of these transplants on patients' health.

To participate in this study, individuals must be at least 18 years old, have a documented HIV infection, and meet certain health criteria, like having a stable immune system indicated by a specific blood test. Participants should not have serious health issues that could complicate their treatment or the study. Those who join can expect to receive regular check-ups and support throughout the trial to monitor their health and the success of the transplant. This study aims to provide important insights that could improve kidney transplant options for people living with HIV.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participant meets local criteria for kidney transplant.
  • Participant is able to understand and provide informed consent.
  • Participant has documented HIV infection by any licensed assay or documented history of detectable HIV-1 RNA.
  • Participant is ≥ 18 years old.
  • HIV-1 RNA \< 50 copies/mL. Viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \> 200 copies/mL.
  • Participant is not suffering from significant wasting (e.g. body mass index \<21) thought to be related to HIV disease.
  • Exclusion Criteria:
  • Participant has prior progressive multifocal leukoencephalopathy (PML), cryptosporidiosis of \> 1 month, or primary central nervous system (CNS) lymphoma.
  • Participant is pregnant or breastfeeding.
  • Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

About Johns Hopkins University

Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.

Locations

San Francisco, California, United States

Boston, Massachusetts, United States

New York, New York, United States

Los Angeles, California, United States

Birmingham, Alabama, United States

Baltimore, Maryland, United States

New Orleans, Louisiana, United States

Chicago, Illinois, United States

Pittsburgh, Pennsylvania, United States

New Haven, Connecticut, United States

New York, New York, United States

San Diego, California, United States

New York, New York, United States

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Christine Durand, MD

Principal Investigator

Johns Hopkins University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported